SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-20-037798
Filing Date
2020-08-06
Accepted
2020-08-06 16:29:05
Documents
63
Period of Report
2020-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q ntla-10q_20200630.htm   iXBRL 10-Q 2743606
2 EX-10.3 ntla-ex103_272.htm EX-10.3 63208
3 EX-31.1 ntla-ex311_6.htm EX-31.1 17025
4 EX-31.2 ntla-ex312_11.htm EX-31.2 17043
5 EX-32.1 ntla-ex321_7.htm EX-32.1 6269
  Complete submission text file 0001564590-20-037798.txt   10209473

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA ntla-20200630.xsd EX-101.SCH 51839
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE ntla-20200630_cal.xml EX-101.CAL 33130
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE ntla-20200630_def.xml EX-101.DEF 183321
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE ntla-20200630_lab.xml EX-101.LAB 403335
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ntla-20200630_pre.xml EX-101.PRE 308338
11 EXTRACTED XBRL INSTANCE DOCUMENT ntla-10q_20200630_htm.xml XML 2349056
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

IRS No.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37766 | Film No.: 201082151
SIC: 2835 In Vitro & In Vivo Diagnostic Substances